| Literature DB >> 34067930 |
Massimo De Majo1, Giulia Donato1, Marisa Masucci1, Cyndi Mangano1, Maria Flaminia Persichetti1, Luigi Liotta1, Giuseppe Mazzullo1, Rosanna Visalli2, Marco Quartuccio1, Nicola Maria Iannelli1, Santo Cristarella1, Maria Grazia Pennisi1.
Abstract
Canine leishmaniosis (CanL) is responsible for splenic pathological changes. The main features detectable from ultrasound examination are splenomegaly and diffuse alterations of the echostructure. The study aimed to highlight whether these ultrasound changes are related to the severity of the disease or to a modification of splenic microvascularization that can be detected in vivo through contrast-enhanced ultrasonography (CEUS). Twenty-five adult dogs tested for CanL were enrolled in this prospective, controlled study and staged according to LeishVet guidelines. Bidimensional ultrasonography revealed that splenomegaly was seen in 50% of the affected dogs, and diffuse parenchymal changes were seen in more than 60% of dogs with splenomegaly, showing a positive correlation with severity of the disease; therefore, splenomegaly could be of prognostic significance. CEUS showed that a persistent heterogeneous distribution pattern appeared only in spleens with diffuse echostructure alterations. The evaluation of quantitative CEUS parameters regarding the volume and velocity of flow in three regions of interest did not show differences between affected and control dogs. Diffuse spleen microvascular modifications evidenced by CEUS were reported for the first time in dogs with CanL. In endemic areas, CanL could be included in the differential diagnoses list when detecting splenic alterations in dogs.Entities:
Keywords: contrast-enhanced ultrasonography; dog; leishmaniosis; spleen
Year: 2021 PMID: 34067930 PMCID: PMC8156246 DOI: 10.3390/ani11051437
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 2.752
Target amplified, primers used for pathogen detection, and fragment length.
| Pathogen | Region Amplified | Primers (5′-3′) | Fragment Length (bp) | Reference |
|---|---|---|---|---|
| 17KDa antigen | TZ15–19 5’-TTC TCA ATT CGG TAA GGG C-3’ | 246 | [ | |
| TZ16–20 5’-ATA TTG ACC AGT GCT ATT TC-3’ | ||||
| Omp A | Rr190.70p ATGGCGAATATTTCTCCAAAA | 532 | [ | |
| Rr190.701n GTTCCGTTAATGGCAGCATCT | ||||
| Rr190.602n AGTGCAGCATTCGCTCCCCCT | ||||
| Omp B | rompB OF GTAACCGGAAGTAATCGTTTCGTAA | 511/425 | [ | |
| rompB OR GCTTTATAACCAGCTAAACCACC | ||||
| rompB SFG IF GTTTAATACGTGCTGCTAACCAA | ||||
| rompB SFG/TG IR GGTTTGGCCCATATACCATAAG | ||||
|
| 16SrRNA | ECC AGAACGAACGCTGGCGGCAAGCC | 480/390 | [ |
| ECB CGTATTACCGCGGCTGCTGGCA | ||||
| ‘‘canis’’ CAATTATTTATAGCCTCTGGCTATAGGA | ||||
| HE3 TATAGGTACCGTCATTATCTTCCCTAT | ||||
|
| msp4 | MSP4AP5 5’-ATGAATTACAGAGAATTGCTTGTAGG-3’ | 849 | [ |
| MSP4AP3 5’-TTAATTGAAAGCAAATCTTGCTCCTATG-3’ | ||||
|
| 16SrRNA | PLATY-F 5’-AAG TCG AAC GGA TTT TTG TC-3′ | ~500 | [ |
| PLATYS-R 5′-CTT TAA CTT ACC GAA CC-3′ | ||||
|
| htpB | Q5 (5′-GCG GGT GAT GGT ACC ACA ACA-3′) | 501 | [ |
| Q3 (5′-GGC AAT CAC CAA TAA GGG CCG-3′) | ||||
| Q6 (5′-TT GCT GGA ATG AAC CCC A-3′) | 325 | |||
| Q4 (5′-TC AAG CTC CGC ACT CAT G-3′) | ||||
|
| ssu-rDNA | PIRO-A 5′AATACCCAATCCTGACACAGGG 3’ | ~400 | [ |
| PIRO-B 5’TTAAATACGAATGCCCCCAAC 3’ |
Figure 1Ultrasound patterns of the spleen in L. infantum-infected dogs: (a) moth-eaten pattern and (b) marbled pattern. F: probe’s frequency; D: distance; G: gain; FR: frame rate; DR: dynamic range; AP: acoustic power; MI: mechanical index; TIS: tissue imaging specific; M9: ultrasound system. Green arrow: ultrasound focal point.
Clinical classification of dogs into groups according to LeishVet guidelines [1]. ICH (infected clinically health).
| Clinical Classification | Number of Dogs (%) |
|---|---|
| ICH | 1 (4.5) |
| Stage I (mild disease) | 5 (22.8) |
| Stage II (moderate disease) | |
| IIa | 9 (40.9) |
| IIb | 1 (4.5) |
| Stage III (severe disease) | 2 (9.1) |
| Stage IV (very severe disease) | 4 (18.2) |
L. infantum molecular positivity and parasite loads in the examined samples.
| Samples | Tested Samples | Positive Samples (%) | Parasite Load |
|---|---|---|---|
| Conjunctival swabs | 52 | 1 (1.9) | 85 |
| Oral swabs | 26 | 1 (3.8) | 115 |
| Auricular swabs | 25 | 2 (8) | 15–430 |
| K2EDTA samples | 26 | 4 (15.4) | 30–70 |
| Lymph node aspirates | 15 | 9 (60) | 110–6400 |
| Spleen aspirates | 26 | 8 (30.8) | 10–18,000 |
| Nodule aspirates | 2 | 1 (50) | 130 |
Frequency of clinical signs of dogs with canine leishmaniosis (CanL) and control dogs.
| Clinical Signs | Number of Dogs (%) | |
|---|---|---|
| Dogs with CanL | Control Dogs | |
| Low Body Condition Score (BCS/9) | 8 (36.4) | 0 |
| Low Muscle Condition Score (MCS/4) | 5 (22.7) | 0 |
| Decreased appetite | 1 (4.5) | 0 |
| Lethargy | 0 | 0 |
| Fever | 0 | 0 |
| Lymphadenomegaly | 17 (77.3) | 1 (33.3) |
| Local | 15 (68.2) | 0 |
| Generalized | 2 (9.1) | 1 (33.3) |
| Skin lesionsNodular dermatitis | 9 (40.9)3 (13.6) | 0- |
| Ulcerative dermatitis | 1 (4.5) | - |
| Squamous dermatitis | 4 (18.2) | - |
| Alopecia | 5 (22.7) | - |
| Splenomegaly | 8 (36.4) | 0 |
| Epistaxis | 0 | 0 |
| Ocular lesions | 6 (27.3) | 0 |
| Blepharoconjunctivitis | 4 (18.2) | - |
| Conjunctival granulomas | 0 | - |
| Keratouveitis | 2 (9.1) | - |
Frequency of hematologic and biochemical alterations of dogs with canine leishmaniosis (CanL) and control dogs. * Thrombocytopenia was not confirmed on blood smears in one CanL dog and in one control dog. MCV (mean red blood cell volume), MCHC (mean corpuscular hemoglobin concentration), RDW (red blood cell distribution width), BUN (blood urea nitrogen), TP (total proteins), ALT (alanine aminotransferase), AST (aspartate aminotransferase), UPC (urine-specific gravity), WRI (within the reference interval).
| Parameter (units) | High (%) | Low (%) | WRI (%) | Reference Interval | |||
|---|---|---|---|---|---|---|---|
| Dogs with CanL | Control Dogs | Dogs with CanL | Control Dogs | Dogs with CanL | Control Dogs | ||
|
| |||||||
| Red blood cells (M/µL) | 2 (9.1) | 1 (33.3) | 6 (27.3) | 0 | 14 (63.6) | 2 (66.7) | 5.65–8.87 |
| Hematocrit (%) | 1 (4.6) | 0 | 7 (31.8) | 0 | 14 (63.6) | 3 (100) | 37.3–61.7 |
| Hemoglobin (g/dL) | 1 (4.5) | 0 | 9 (40.9) | 1 (33.3) | 12 (54.6) | 2 (66.7) | 13.1–20.5 |
| MCV (fL) | 0 | 0 | 4 (18.2) | 0 | 18 (81.8) | 3 (100) | 61.6–73.5 |
| MCHC (g/dL) | 0 | 0 | 3 (13.6) | 0 | 19 (86.4) | 3 (100) | 32.0–37.9 |
| RDW (%) | 0 | 0 | 0 | 0 | 22 | 3 (100) | 13.6–21.7 |
| Reticulocytes (K/µL) | 1 (4.5) | 1 (33.3) | 0 | 0 | 21 (95.5) | 2 (66.7) | 10.0–110.0 |
| White blood cells (K/µL) | 1 (4.5) | 0 | 0 | 0 | 21 (95.5) | 3 (100) | 5.05–16.76 |
| Neutrophils (K/µL) | 1 (4.5) | 0 | 0 | 1 (33.3) | 21 (95.5) | 2 (66.7) | 2.95–11.64 |
| Lymphocytes (K/µL) | 0 | 0 | 3 (13.6) | 0 | 19 (86.4) | 3 (100) | 1.05–5.10 |
| Monocytes (K/µL) | 3 (13.6) | 0 | 0 | 0 | 19 (86.4) | 3 (100) | 0.16–1.12 |
| Eosinophils (K/µL) | 7 (31.8) | 1 (33.3) | 2 (9.1) | 0 | 13 (59.1) | 2 (66.7) | 0.06–1.23 |
| Basophils (K/µL) | 3 (13.6) | 0 | 0 | 0 | 19 (86.4) | 3 (100) | 0.00–0.10 |
| Platelets (K/µL) | 0 | 0 | 5 * (22.7) | 1 *(33.3) | 17 (77.3) | 2 (66.7) | 148–484 |
|
| |||||||
| BUN (mg/dL) | 3 (13.6) | 0 | 0 | 0 | 19 (86.4) | 3 (100) | 10–25 |
| Creatinine (mg/dL) | 1 (4.5) | 0 | 0 | 0 | 21 (95.5) | 3 (100) | <2 |
| TP (g/dL) | 2 (9.1) | 1 (33.3) | 1 (4.5) | 0 | 19 (86.4) | 2 (66.7) | 5.5–7.8 |
| Albumin (g/dL) | 0 | 0 | 6 (27.3) | 1 (33.3) | 16 (72.7) | 2 (66.7) | 2.5–3.5 |
| ALT (UI/L) | 2 (9.1) | 0 | 0 | 0 | 20 (90.9) | 3 (100) | <100 |
| AST (UI/L) | 0 | 0 | 0 | 0 | 22 | 3 (100) | <90 |
| UPC (no units) | 7 (31.8) | 0 | 0 | 0 | 15 (68.2) | 3 (100) | <0.5 |
Vector-borne pathogen (VBP) overall antibody prevalence of dogs with canine leishmaniosis (CanL) and control dogs.
| Pathogens | Seroreactive Dogs (%) | |
|---|---|---|
| CanL | Control Dogs | |
|
| 3/22 (13.6) | 1/3 (33.3) |
|
| 13/22 (59.1) | 3/3 (100) |
|
| 5/21 (23.8) | 2/3 (66.7) |
|
| 2/22 (9.1) | 1/3 (33.3) |
Figure 2Absence of signal at Color Power Doppler (CPD) in hypoechoic areas of the moth-eaten pattern of the spleen. F: probe’s frequencies; D: distance; G: gain; FR: frame rate; DR: dynamic range; AP: acoustic power; MI: mechanichal index; TIS: tissue imaging specific; M9: ultrasound system. Blue and green arrows: focal points.
Figure 3Normal spleen images acquired during CEUS (contrast-enhanced ultrasonography) exam. (a) Enhancement of the splenic arteries at 8 s after contrast injection; (b) beginning of heterogeneous phase of enhancement 10 s after contrast injection; (c) homogeneous enhancement at 60 s after contrast injection. F: probe’s frequencies; D: distance; G: gain; FR: frame rate; DR: dynamic range; AP: acoustic power; MI: mechanichal index; TIS: tissue imaging specific; M9: ultrasound system; T: tissue; C: contrast. Green arrows: focal points.
Figure 4Moth-eaten spleen images acquired during CEUS exam. The heterogeneous enhancement of the parenchyma was persistently observed at: (a) 13 s, (b) 33 s, and (c) 60 s after contrast injection. F: probe’s frequencies; D: distance; G: gain; FR: frame rate; DR: dynamic range; AP: acoustic power; MI: mechanichal index; TIS: tissue imaging specific; M9: ultrasound system; T: tissue; C: contrast. Green arrows: focal points.
Figure 5CEUS images at the end of the wash-in phase in (a) moth-eaten, (b) marbled (heterogeneous enhancement), and (c) normal (homogeneous enhancement) spleens. F: probe’s frequencies; D: distance; G: gain; FR: frame rate; DR: dynamic range; AP: acoustic power; MI: mechanichal index; TIS: tissue imaging specific; M9: ultrasound system; T: tissue; C: contrast. Green arrows: focal points.
Results from ANOVA for quantitative CEUS parameters in relations to ROI (region of interest) areas. GOF: goodness of fit; BI: base intensity; AT: arrival time; TTP: time to peak; PI: peak intensity; AS: ascending slope; DT/2: time when the intensity is half the value of the peak intensity; DS: descending slope; AUC: area under curve; and SEM: standard error of the mean.
| GOF | BI | AT | TTP | PI | AS | DT/2 | DS | AUC | |
|---|---|---|---|---|---|---|---|---|---|
| ROI1 | 0.83 | 15.62 | 2.27 | 31.02 | 21.33 | 0.18 | 109.72 | −0.03 | 3303.61 |
| ROI2 | 0.82 | 15.90 | 2.18 | 28.53 | 21.47 | 0.15 | 109.08 | −0.03 | 3283.48 |
| ROI3 | 0.90 | 15.87 | 1.30 | 30.28 | 21.44 | 0.14 | 116.12 | −0.03 | 3335.92 |
| SEM | 0.05 | 0.21 | 0.08 | 1.71 | 2.65 | 0.15 | 2.55 | 0.09 | 18.38 |
| 0.06 | 0.48 | 0.08 | 0.24 | 0.49 | 0.30 | 0.16 | 0.12 | 0.38 |